Noninternalizing targeted cytotoxics for cancer therapy

Molecular Pharmaceutics
Giulio Casi, Dario Neri

Abstract

Conventional cancer chemotherapy is limited by the fact that small organic cytotoxic agents typically do not preferentially localize at the tumor site, causing unwanted toxicities to normal organs and limiting dose escalation to therapeutically active regimens. In principle, antibodies and other ligands could be used for the selective pharmacodelivery of cytotoxic agents to the tumor environment. While traditionally internalizing ligands have been used for such targeting applications, increasing experimental evidence suggests that the ligand-based delivery of anticancer drugs to the extracellular space in the tumor, followed by suitable release strategies, may mediate a potent anticancer activity. In this review, we outline the main requirements for the development of noninternalizing targeted cytotoxics.

References

Jan 1, 1994·Annual Review of Immunology·G WinterH R Hoogenboom
Aug 8, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·H MaedaT Konno
Jun 29, 2002·Nuclear Medicine and Biology·David P TrumpMark A Green
Sep 28, 2002·International Journal of Cancer. Journal International Du Cancer·Laura BorsiLuciano Zardi
Jun 2, 2005·Nature Reviews. Cancer·Dario Neri, Roy Bicknell
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Frank G van SchaijkOtto C Boerman
Oct 24, 2006·Proceedings of the National Academy of Sciences of the United States of America·Mihaela GinjJean Claude Reubi
Jan 11, 2007·Cancer Research·Mark S DennisRalph Schwall
May 8, 2007·Cancer Research·Joseph A ReddyChristopher P Leamon
Feb 14, 2008·International Journal of Cancer. Journal International Du Cancer·Alessandra VillaDario Neri
Mar 4, 2008·Nuclear Medicine and Biology·Paul J YazakiAndrew Raubitschek
Feb 4, 2009·Proceedings of the National Academy of Sciences of the United States of America·Héctor Pérez MontoyoE Sally Ward
Mar 23, 2010·Nature Reviews. Drug Discovery·Trevor T HanselAndrew J T George
May 29, 2010·European Journal of Nuclear Medicine and Molecular Imaging·Astrid A M van der VeldtMark Lubberink
Jul 21, 2010·Current Opinion in Chemical Biology·Stephen C AlleyPeter D Senter
Oct 13, 2010·Journal of Medicinal Chemistry·Sumith A KularatnePhilip S Low
Dec 29, 2010·ACS Chemical Biology·Fabian BullerDario Neri
Dec 14, 2011·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Alexander B StillebroerWim J G Oyen
Dec 17, 2011·Angewandte Chemie·Gonçalo J L BernardesDario Neri
Jan 11, 2012·Methods in Enzymology·K Dane WittrupJohn J Rhoden
May 12, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Paola A ErbaGiuliano Mariani
Jun 7, 2012·Bioconjugate Chemistry·Iontcho R Vlahov, Christopher P Leamon
Jan 22, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Derrek A HeuvelingGuus A M S van Dongen
Jan 29, 2013·ChemMedChem·Vanessa Baeriswyl, Christian Heinis
Apr 27, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Astrid A M van der VeldtAdriaan A Lammertsma
Dec 18, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Bert-Ram SahIrene A Burger
Mar 29, 2014·Accounts of Chemical Research·Raphael M FranziniJörg Scheuermann
Mar 29, 2014·Angewandte Chemie·Ravi V J ChariWayne C Widdison
Apr 22, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jiyuan Yang, Jindřich Kopeček
Apr 25, 2014·Molecular Cancer Therapeutics·Katrin L GutbrodtDario Neri
Apr 29, 2014·Molecular Pharmaceutics·Kathrin FuhrmannJean-Christophe Leroux
Apr 30, 2014·Cancer Immunology Research·Gian Luca PoliAndrea Bruno
May 14, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ruth Duncan
Aug 19, 2014·Trends in Biochemical Sciences·Toby Passioura, Hiroaki Suga
Sep 11, 2014·Molecular Cancer Therapeutics·Thomas ListDario Neri
Apr 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R T MorrisW A Harb

❮ Previous
Next ❯

Citations

Jul 2, 2016·International Journal of Pharmaceutics·Christian ReichertGerrit Borchard
Jan 3, 2020·Chemical Communications : Chem Comm·Marcos FernándezVijay Chudasama
Jan 7, 2020·Médecine sciences : M/S·Alain BeckNicolas Joubert
Jun 25, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·David Dahlgren, Hans Lennernäs
Sep 18, 2020·Pharmaceuticals·Nicolas JoubertCaroline Denevault-Sabourin
Sep 5, 2017·Journal of Controlled Release : Official Journal of the Controlled Release Society·Alberto Dal CorsoDario Neri
Aug 23, 2019·Journal of Inorganic Biochemistry·Virginia Del Solar, María Contel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Current Opinion in Chemical Biology
Florent Samain, Giulio Casi
Biochimica Et Biophysica Acta
Patrizia AlessiDario Neri
Biochimica Et Biophysica Acta
Christoph Schliemann, Dario Neri
© 2022 Meta ULC. All rights reserved